The first full day of sessions at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam was filled with new scientific findings shared by researchers from around the world. In a Facebook Live interview with HIV.gov, Carl Dieffenbach, Ph.D., discussed highlights of three studies presented today at the conference, including:
- an update on a potential association between the HIV treatment medication dolutegravir and birth defects;
- additional research on the effectiveness of HIV treatment as prevention among gay male serodifferent couples; and
- a study on whether there may be drug-drug interactions between PrEP and feminizing hormone therapy for transgender women.
Dr. Dieffenbach is the Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID).